Clinical Management of Immune Checkpoint Inhibitor Toxicities
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 90 Minutes
The practice of oncology is complex and the therapeutic landscape is quickly evolving. With the development of new and effective oncological treatments, also comes new adverse effects which often need to be professionally mitigated. During this webcast, expert faculty will discuss identification and management of immune related adverse events caused by immune checkpoint inhibitors.
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
1. Recognize the spectrum of immune-related adverse events (irAEs) that occur as a consequence of immune checkpoint inhibitor (ICI) therapy
2. Discuss strategies for managing (irAE) in the corticosteroid- refractory setting
3. Identify challenges and unknowns in management of various irAEs
Lisa Kottschade, APRN, CNP
Ms. Kottschade is a Nurse Practitioner and an Associate Professor of Oncology at Mayo Clinic College of Medicine. Ms. Kottschade earned her bachelor of science in nursing degree from Winona State University in 1996 and her Masters of Science in Nursing Degree from Saint Louis University in 2005.
Ms. Kottschade has worked in oncology for over 25 years with 17 of those in the treatment of malignant melanoma and other skin cancers. She has a special interest in predicting, monitoring and management of treatment-related side effects in patients undergoing systemic therapy for the treatment of melanoma. She currently leads the Immunotherapy Toxicity Working Group at Mayo Clinic, which is a multi-disciplinary group of specialists dedicated to the treatment of irAE’s. Ms. Kottschade is also the Chief Operations Officer of the Midwest Melanoma Partnership, an 18 institution research consortium dedicated to melanoma research and patient education.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Lisa Kottschade, APRN, CNP was on Advisory Board with BMS, Immunocore, and Novartis, but relationship has ended, during the past 24 months. *
- 0.75 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Access to the internet is required.
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above